[go: up one dir, main page]

ATE432265T1 - Pyrimidinon verbindungen - Google Patents

Pyrimidinon verbindungen

Info

Publication number
ATE432265T1
ATE432265T1 AT04077397T AT04077397T ATE432265T1 AT E432265 T1 ATE432265 T1 AT E432265T1 AT 04077397 T AT04077397 T AT 04077397T AT 04077397 T AT04077397 T AT 04077397T AT E432265 T1 ATE432265 T1 AT E432265T1
Authority
AT
Austria
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AT04077397T
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE432265T1 publication Critical patent/ATE432265T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04077397T 1999-05-01 2000-04-25 Pyrimidinon verbindungen ATE432265T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds

Publications (1)

Publication Number Publication Date
ATE432265T1 true ATE432265T1 (de) 2009-06-15

Family

ID=26243514

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00920741T ATE283845T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen
AT04077397T ATE432265T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00920741T ATE283845T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Country Status (29)

Country Link
US (2) US6953803B1 (de)
EP (2) EP1479671B1 (de)
JP (1) JP2002543190A (de)
KR (1) KR20020012200A (de)
CN (1) CN1286822C (de)
AR (1) AR023777A1 (de)
AT (2) ATE283845T1 (de)
AU (1) AU766003B2 (de)
BR (1) BR0010220A (de)
CA (1) CA2371671A1 (de)
CO (1) CO5170521A1 (de)
CZ (1) CZ20013904A3 (de)
DE (2) DE60016397T2 (de)
DK (1) DK1175408T3 (de)
ES (1) ES2233361T3 (de)
HK (1) HK1044757B (de)
HU (1) HUP0201122A3 (de)
IL (1) IL146210A0 (de)
MX (1) MXPA01011186A (de)
MY (1) MY136037A (de)
NO (1) NO20015329D0 (de)
NZ (1) NZ515137A (de)
PE (1) PE20010070A1 (de)
PL (1) PL351690A1 (de)
PT (1) PT1175408E (de)
SI (1) SI1175408T1 (de)
TR (1) TR200103216T2 (de)
UY (1) UY26132A1 (de)
WO (1) WO2000066567A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351690A1 (en) * 1999-05-01 2003-06-02 Smithkline Beecham Plc Pyrimidinone compounds
PL209824B1 (pl) 2000-02-16 2011-10-31 Smithkline Beecham Plc 1-(N-2-(dietyloamino)etylo)-N-(4-(4-trifluorometylo-fenylo)benzylo)aminokarbonylometylo)-2-(4-fluorobenzylo)tio-5,6-trimetylenopirymidyn-4-on, jego zastosowania i zawierająca go farmaceutyczna kompozycja
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
WO2005003118A1 (de) * 2003-07-02 2005-01-13 Bayer Healthcare Ag Amid-substituierte 1,2,4-triazin-5 (2h)-one zur behandlung von chronisch inflammatorischen krankheiten
EP2290094A1 (de) 2004-04-16 2011-03-02 Glaxo Group Limited Verfahren zur bestimmung von lp-pla2-aktivität und hemmung von lp-pla2 aktivität
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
AU2007353454C8 (en) 2007-05-11 2014-04-24 Rowan University Methods of treatment and prevention of neurodegenerative diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
AR081399A1 (es) 2010-05-17 2012-08-29 Glaxo Group Ltd Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
BR112013013898B1 (pt) 2010-12-06 2021-10-13 Glaxo Group Limited Compostos de pirimidinona, composição farmacêutica compreendendo ditos compostos e usos dos mesmos para o tratamento de doença de alzheimer e aterosclerose
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
JP2014521611A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
CN103917529B (zh) * 2011-11-11 2016-08-17 辉瑞大药厂 2-硫代嘧啶酮类
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
ES2642762T3 (es) 2013-01-25 2017-11-20 Glaxosmithkline Intellectual Property Development Limited Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
WO2021089032A1 (zh) 2019-11-09 2021-05-14 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
DE69816471T2 (de) * 1997-11-06 2004-05-27 Smithkline Beecham P.L.C., Brentford Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
EP1105377B1 (de) 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinonderivate zur behandlung von atheroscleros
PL351690A1 (en) * 1999-05-01 2003-06-02 Smithkline Beecham Plc Pyrimidinone compounds

Also Published As

Publication number Publication date
EP1175408B1 (de) 2004-12-01
AU4120300A (en) 2000-11-17
CZ20013904A3 (cs) 2002-04-17
HUP0201122A3 (en) 2003-11-28
DK1175408T3 (da) 2005-04-11
IL146210A0 (en) 2002-07-25
CN1286822C (zh) 2006-11-29
JP2002543190A (ja) 2002-12-17
CO5170521A1 (es) 2002-06-27
NO20015329L (no) 2001-10-31
TR200103216T2 (tr) 2002-04-22
NO20015329D0 (no) 2001-10-31
EP1479671A1 (de) 2004-11-24
DE60016397T2 (de) 2005-12-01
AU766003B2 (en) 2003-10-09
MY136037A (en) 2008-08-29
PT1175408E (pt) 2005-04-29
DE60016397D1 (de) 2005-01-05
HUP0201122A2 (en) 2002-08-28
US20040167142A1 (en) 2004-08-26
KR20020012200A (ko) 2002-02-15
AR023777A1 (es) 2002-09-04
UY26132A1 (es) 2000-12-29
SI1175408T1 (en) 2005-04-30
ES2233361T3 (es) 2005-06-16
PE20010070A1 (es) 2001-03-10
HK1044757A1 (en) 2002-11-01
EP1479671B1 (de) 2009-05-27
ATE283845T1 (de) 2004-12-15
MXPA01011186A (es) 2002-08-12
HK1044757B (en) 2005-07-08
NZ515137A (en) 2003-10-31
BR0010220A (pt) 2002-05-14
CA2371671A1 (en) 2000-11-09
CN1358175A (zh) 2002-07-10
DE60042286D1 (de) 2009-07-09
US7115616B2 (en) 2006-10-03
US6953803B1 (en) 2005-10-11
PL351690A1 (en) 2003-06-02
EP1175408A1 (de) 2002-01-30
WO2000066567A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
DE60016397D1 (de) Pyrimidinon verbindungen
CY2015035I1 (el) Ενωσεις πυριμιδινης
ATE344248T1 (de) Antibakterielle verbindungen
EE200100502A (et) Ühendid
NO20024127L (no) Pyrimidin-forbindelser
NO20015536D0 (no) FAP-aktiverte anti-tumor-forbindelser
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
EE200200224A (et) Uudsed ühendid
ATE283049T1 (de) Antibakterielle verbindungen
DE69807397D1 (de) Triazinylaminostilben Verbindungen
NO20021503D0 (no) Kinazolinoner
ATE405580T1 (de) Antithrombotische verbindungen
DE69914594D1 (de) Aryl-annellierte azapolycyclische verbindungen
NO20013769L (no) Kalsilytiske forbindelser
NO20021502D0 (no) Kinazolinoner
ATE384726T1 (de) Bicyclische heteroaromatische verbindungen
NO20020466L (no) Kalsilytiske forbindelser
DE60035826D1 (de) Entfernungsmesser
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
NO20014262D0 (no) Tiazoloindolinon-forbindelser
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9903080D0 (sv) Novel compounds
SE9902903D0 (sv) Novel compounds
SE9903838D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties